Marsh & McLennan Companies, Inc. (MRSH) Stock Price Today
Aura AI Summary
Key Stats
- $85.91BMarket Cap
- -Volume
- FinancialsSector
- $213.5752W High
- $157.3252W Low
- -Typical Hold Time
- $106.75BEnterprise Value
- 2.22%Div Yield
- -Trading Activity
Track Marsh & McLennan Companies, Inc. (MRSH) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Marsh & McLennan Companies, Inc. has traded between a low of $157.32 and a high of $213.57, highlighting its annual price range. Buy and sell Marsh & McLennan Companies, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Most Recent News
AI use in cybersecurity jumps to 78% in 2026, but governance and failures lag behind.
The 2026 SANS AI Survey reveals rapid AI adoption in cybersecurity, with 78% of organizations using AI, up from 50% last year. However, governance structures and formal audit frameworks have not kept pace, leading to increased AI-related failures in ...

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.
Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.